Eight year patient reported outcome data of the first 150 Dutch men on active surveillance in the Prostate cancer Research International Active Surveillance study (PRIAS)

2019 ◽  
Vol 18 (1) ◽  
pp. e1707-e1708
Author(s):  
L.D.F. Venderbos ◽  
R.C.N. Van Den Bergh ◽  
C.H. Bangma ◽  
M.J. Roobol
Keyword(s):  
Prostate Cancer ◽  
Cancer Research ◽  
Active Surveillance ◽  
Patient Reported Outcome ◽  
Outcome Data ◽  
Surveillance Study ◽  
Patient Reported ◽  
Prostate Cancer Research

Short-term outcomes of the prospective multicentre ‘Prostate Cancer Research International: Active Surveillance’ study

2010 ◽  
Vol 105 (7) ◽  
pp. 956-962 ◽  
Author(s):  
Roderick C.N. van den Bergh ◽  
Hanna Vasarainen ◽  
Henk G. van der Poel ◽  
Jenneke J. Vis-Maters ◽  
John B. Rietbergen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Research ◽  
Active Surveillance ◽  
Surveillance Study ◽  
Short Term ◽  
Prostate Cancer Research

scholarly journals Cohort profile: the Alberta Prostate Cancer Research Initiative (APCaRI) Registry and Biorepository facilitates technology translation to the clinic through the use of linked, longitudinal clinical and patient-reported data and biospecimens from men in Alberta, Canada

BMJ Open ◽  
2020 ◽  
Vol 10 (10) ◽  
pp. e037222
Author(s):  
Catalina Vasquez ◽  
Michael Kolinsky ◽  
Rume Djebah ◽  
Maxwell Uhlich ◽  
Bryan Donnelly ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Research ◽  
Data Entry ◽  
Patient Reported Outcome ◽  
Men 2 ◽  
Data Entry Error ◽  
Research Initiative ◽  
Patient Reported ◽  
Prostate Cancer Research ◽  
Reported Data

PurposeThe Alberta Prostate Cancer Research Initiative (APCaRI) Registry and Biorepository was established in 2014 by the APCaRI to facilitate the collection of clinical and patient-reported data, biospecimen, to measure prostate cancer outcomes and to support the development and clinical translation of innovative technologies to better diagnose and predict outcomes for patients with prostate cancer.ParticipantsMen suspected with prostate cancer and referred to Urology centres in Alberta were enrolled in the APCaRI 01 study, while men with a prior prostate cancer diagnosis participated in the APCaRI 03 study from 1 July 2014 to 30 June 2019. The APCaRI Registry and Biorepository links biospecimens and data from a wide representation of patients drawn from an Alberta population of more than 4 million.Findings to dateFrom 1 July 2014 to 30 June 2019, total APCaRI 01 and 03 study recruitment was 3754 men; 142 (4%) of these men withdrew in full, 65 men (2%) withdrew biospecimens and 123 men (3%) died of any cause. Over this same time, 8677 patient-reported outcome measure (PROM) surveys and 7368 biospecimens were collected and are available from the registry and biorepository, respectively. The data entry error rate was 0.8% and 0.95% for critical and non-critical values, respectively, and 1.8% for patient-reported surveys.Future plansThe APCaRI Registry and Biorepository will collect longitudinal data and PROM surveys until 2024, patient outcomes up to 25 years after recruitment and biospecimen storage for up to 25 years. The APCaRI cohorts will continue to provide data and samples to researchers conducting retrospective studies. The richness of the data and biospecimens will complement many different research questions, ultimately to improve the quality of care for men with prostate cancer.

Health-related quality-of-life (HRQoL) analysis from a randomized phase II trial of androgen signaling inhibitors with or without androgen deprivation therapy (ADT) for castration-sensitive prostate cancer: LACOG 0415.

2021 ◽  
Vol 39 (6_suppl) ◽  
pp. 64-64
Author(s):  
Andrey Soares ◽  
Diogo Assed Bastos ◽  
Fabio A. B. Schutz ◽  
Eduardo Cronemberger ◽  
Murilo Luz ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Locally Advanced ◽  
Patient Reported Outcome ◽  
Abiraterone Acetate ◽  
Outcome Data ◽  
Rank Test ◽  
Emotional Wellbeing ◽  
Patient Reported ◽  
Related Quality

64 Background: LACOG0415 is a 3-arm randomized trial evaluating ADT with abiraterone acetate plus prednisone (ADT+AAP), apalutamide alone (APA) or apalutamide with AAP (APA+AAP) for patients with locally-advanced, high-risk biochemical recurrence or metastatic castration-sensitive prostate cancer (ASCO 2020). In this trial, ADT+AAP and APA+AAP achieved the primary endpoint of percentage of patients with PSA ≤ 0.2 ng/mL at week 25. Apalutamide alone showed a high PSA decline > 50% rate, but did not achieve the pre-specified PSA threshold. Here we report patient-reported outcome data using Functional Assessment of Cancer Therapy-Prostate (FACT-P). Methods: HRQoL was measured in the overall population using the FACT-P questionnaire, comprising 5 subscales: physical wellbeing (PWB), functional wellbeing (FWB), emotional wellbeing (EWB), social/family wellbeing (SFWB), and prostate cancer subscale (PCS). Scores for each patient were measured at baseline and every four weeks until week 25. Questionnaire completion was defined as ≥ 1 question answered at an assessment time point. Analysis of HRQoL change from baseline and deterioration included only patients with baseline and ≥ 1 postbaseline score. Differences greater than 10-points in FACT-P total score and differences greater than 3-points in PWB, FWB, EWB, SFWB, and PCS scores were considered clinically significant. The time-to-event endpoint was estimated by Kaplan-Meier method and compared by stratified log-rank test. Results: 128 patients were included in LACOG0415 trial and 122 of them completed the HRQoL assessments (ranging from 95.3% at baseline to 79.7% at week 25). FACT-P and all subscales scores were similar for all three arms at baseline. There were no meaningful differences in FACT-P scores at baseline and at week 25 between the 3 arms. The subscales scores also showed no statistically differences at baseline and at week 25. Time to FACT-P deterioration did not show any statistically difference between three arms ( P=0.3371). Conclusions: ADT free alternatives with APA alone or APA+AAP did not show meaningful differences in HRQoL in patients with advanced castration-sensitive prostate cancer compared to ADT+AAP. The short follow-up period limited the ability to explore differences in HRQoL after 25 weeks. Larger studies with longer follow-up are needed to further evaluate HRQoL with ADT-free strategies. Clinical trial information: NCT02867020. [Table: see text]

scholarly journals Complications after prostate biopsies in men on active surveillance and its effects on receiving further biopsies in the Prostate cancer Research International: Active Surveillance (PRIAS) study

2016 ◽  
Vol 118 (3) ◽  
pp. 366-371 ◽  
Author(s):  
Leonard P. Bokhorst ◽  
Inari Lepistö ◽  
Yoshiyuki Kakehi ◽  
Chris H. Bangma ◽  
Tom Pickles ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Research ◽  
Active Surveillance ◽  
Prostate Biopsies ◽  
Prostate Cancer Research

27 Protocol based versus non-protocol based discontinuation in the Prostate cancer Research International: Active Surveillance (PRIAS) study

2014 ◽  
Vol 13 (1) ◽  
pp. e27-e27a
Author(s):  
L.P. Bokhorst ◽  
J.W. Salman ◽  
L.D. Venderbos ◽  
A. Rannikko ◽  
R. Valdagni ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Research ◽  
Active Surveillance ◽  
Prostate Cancer Research

Indications for intervention during active surveillance of prostate cancer: a comparison of the Johns Hopkins and Prostate Cancer Research International Active Surveillance (PRIAS) protocols

2014 ◽  
Vol 115 (2) ◽  
pp. 216-222 ◽  
Author(s):  
Max Kates ◽  
Jeffrey J. Tosoian ◽  
Bruce J. Trock ◽  
Zhaoyong Feng ◽  
H. Ballentine Carter ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Research ◽  
Active Surveillance ◽  
Prostate Cancer Research
Sign in / Sign up

Export Citation Format

Share Document